In accordance with the national decision-making and deployment, the National Health Insurance Administration, together with the Ministry of Human Resources and Social Security and other departments, organized the adjustment of the national basic medical insurance, work-related injury insurance and maternity insurance drug catalogue in 2023, which has been successfully concluded.
Today (13th), the National Health Insurance Administration held a press conference to announce the results of the adjustment of the 2023 National Medical Insurance Drug List. Let's look at it together
This year is the sixth consecutive year that the National Medical Insurance Drug List has been adjusted, and after the corresponding proceduresA total of 126 drugs have been added to the National Medical Insurance Drug List, and 1 drug has been transferred out of the List. In the negotiation and bidding process, 143 drugs outside the catalogue participatedOf these, 121 were successfully negotiated or bidd, with a success rate of 846%，The average price reduction is 617%, the success rate and ** decline are basically the same as in 2022. Overlapping negotiated price reductions and medical insurance reimbursement factors,It is expected to reduce the burden on patients by more than 40 billion yuan in the next two years。Among the new drugs, there are 21 kinds of drugs for tumors, 17 kinds of drugs for new crown and anti-infective, 15 kinds of drugs for chronic diseases such as diabetes, psychiatry, rheumatism and immunity, 15 kinds of drugs for rare diseases (among which avatinib tablets are also drugs for tumors), and 59 kinds of drugs used in other fields. After this round of adjustments,The total number of drugs in the National Medical Insurance Drug List has reached 3,088, including 1,698 kinds of Western medicines and 1,390 kinds of Chinese patent medicines;There are still 892 kinds of Chinese medicine decoction pieces. The level of protection in the fields of chronic diseases, rare diseases, and children's medication has been further improved. Since the establishment of the National Health Insurance Administration, it has carried out the adjustment of the drug catalogue for six consecutive yearsA total of 744 drugs have been added to the National Medical Insurance Drug ListAt the same time, a batch of drugs with uncertain efficacy, clinical abuse or obsolescence will be transferred out of the catalog. The relevant statistics of the Chinese Pharmaceutical Association show that since 2018, the proportion of medical insurance drugs in the use of drugs in medical institutions has increased year by year, the dominant position has been further consolidated, and the rationality of clinical drug use has been actively improved. At the same time,The speed of innovative drugs entering the medical insurance has been significantly accelerated, and the level of commonly used drugs** has decreased significantlyThe level of drug protection for major diseases and special groups has been greatly improved, and the burden of drug use on the masses has been significantly reduced.
Long press **Identify*** or scan the code to view the latest version of the medical insurance drug list
*: China**.com, National Health Insurance Administration, Xinhua News Agency, News Network WeChat.
Editor: Chen Long Proofreader: Yang Yakang.